市售体积测量软件工具在阿尔茨海默病风险人群中的预测效用:海马以外区域是否重要?
基于阿尔茨海默病神经影像学倡议数据,192例基线轻度认知障碍患者接受T1加权MR及3年临床随访,用NeuroQuant和Neuroreader评估单个与联合区域脑体积对转化为阿尔茨海默病的预测效能;海马体积在两种软件中AUC最高(0.69与0.68),联合多体积未提高AUC。
要点
- 海马体积是轻度认知障碍转化为阿尔茨海默病的最佳单一预测指标,两种软件AUC相近(0.69与0.68)。
- 联合多个区域体积未增加预测效能,多变量分析AUC未超过单变量海马体积。
- 在FDA cleared的脑体积软件中,海马体积可作为唯一体积生物标志物用于未来预后研究。
核心结论
- 在FDA cleared的脑体积测量软件提供的多个区域体积指标中,海马体积仍是3年随访预测轻度认知障碍转化为阿尔茨海默病的最佳单一预测指标;联合体积测量未增加额外预后效能。
研究设计与样本
- 研究数据来自阿尔茨海默病神经影像学倡议,192例基线诊断为轻度认知障碍的受试者(平均年龄74.8岁,39%女性),均有基线T1加权MR序列和3年临床随访,分析使用NeuroQuant和Neuroreader两款软件。
诊断标准与关键数值
- 单变量分析11个NeuroQuant和11个Neuroreader区域体积时,海马体积的AUC在NeuroQuant为0.69、在Neuroreader为0.68,两种软件间无显著差异(P > .05);多变量分析未提高AUC:NeuroQuant logistic回归0.63、随机森林0.60;Neuroreader logistic回归0.65、随机森林0.62。
临床应用与阅片要点
- 原文结论认为,未来在轻度认知障碍中结合人口学和其他生物标志物的预后研究,有理由将海马体积作为唯一体积生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Alzheimer disease is a prevalent neurodegenerative disease. Computer assessment of brain atrophy patterns can help predict conversion to Alzheimer disease. Our aim was to assess the prognostic efficacy of individual-versus-combined regional volumetrics in 2 commercially available brain volumetric software packages for predicting conversion of patients with mild cognitive impairment to Alzheimer disease.
MATERIALS AND METHODS: Data were obtained through the Alzheimer's Disease Neuroimaging Initiative. One hundred ninety-two subjects (mean age, 74.8 years; 39% female) diagnosed with mild cognitive impairment at baseline were studied. All had T1-weighted MR imaging sequences at baseline and 3-year clinical follow-up. Analysis was performed with NeuroQuant and Neuroreader. Receiver operating characteristic curves assessing the prognostic efficacy of each software package were generated by using a univariable approach using individual regional brain volumes and 2 multivariable approaches (multiple regression and random forest), combining multiple volumes.
RESULTS: On univariable analysis of 11 NeuroQuant and 11 Neuroreader regional volumes, hippocampal volume had the highest area under the curve for both software packages (0.69, NeuroQuant; 0.68, Neuroreader) and was not significantly different (P > .05) between packages. Multivariable analysis did not increase the area under the curve for either package (0.63, logistic regression; 0.60, random forest NeuroQuant; 0.65, logistic regression; 0.62, random forest Neuroreader).
CONCLUSIONS: Of the multiple regional volume measures available in FDA-cleared brain volumetric software packages, hippocampal volume remains the best single predictor of conversion of mild cognitive impairment to Alzheimer disease at 3-year follow-up. Combining volumetrics did not add additional prognostic efficacy. Therefore, future prognostic studies in mild cognitive impairment, combining such tools with demographic and other biomarker measures, are justified in using hippocampal volume as the only volumetric biomarker.
引用
- Tanpitukpongse TP, Mazurowski MA, Ikhena J, et al. Predictive Utility of Marketed Volumetric Software Tools in Subjects at Risk for Alzheimer Disease: Do Regions Outside the Hippocampus Matter? AJNR Am J Neuroradiol. 2017. PMID: 28057634. doi:10.3174/ajnr.A5061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。